Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9358367 | 0.79 | HTR5A (0.44) | HTR5ADRD2DRD3ALDH1A1ADRA2B | |
| SCHEMBL23023377 | 0.75 | HTR5A (0.46) | HTR5ADRD2DRD3ALDH1A1ADRA2B | |
| SCHEMBL9457900 | 0.74 | HTR5A (0.40) | HTR5ADRD2DRD3ADRA2A | |
| SCHEMBL3908655 | 0.73 | HTR5A (0.39) | HTR5ADRD2DRD3 | |
| SCHEMBL13999138 | 0.73 | DRD2 (0.49) | HTR5ADRD2DRD3ALDH1A1ADRA2B | |
| SCHEMBL29823229 | 0.73 | DRD2 (0.49) | HTR5ADRD2DRD3ALDH1A1ADRA2B | |
| SCHEMBL17014343 | 0.72 | HTR5A (0.47) | HTR5ADRD2DRD3ALDH1A1ADRA2B | |
| SCHEMBL26889680 | 0.72 | ADRA2A (0.30) | ADRA2A | |
| SCHEMBL5549331 | 0.72 | KDM1A (0.50) | DRD2 | |
| SCHEMBL18053266 | 0.72 | HTR5A (0.46) | HTR5ADRD2DRD3ALDH1A1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | HTR5A 4855/4885DRD2 4639/4885DRD3 4417/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | HTR5A 4855/4885DRD2 4639/4885DRD3 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.